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STUDY PROTOCOL Open Access
The effect of providing feedback on inhaler
technique and adherence from an
electronic audio recording device, INCA®,
in a community pharmacy setting: study
protocol for a randomised controlled trial
Susan Mary O’Dwyer1,2*, Elaine MacHale3, Imran Sulaiman3, Martin Holmes4, Cian Hughes4, Shona D’Arcy4,
Viliam Rapcan4, Terence Taylor4, Fiona Boland5, Sinthia Bosnic-Anticevich6, Richard B. Reilly4, Sheila A. Ryder1
and Richard W. Costello3,7
Abstract
Background: Poor adherence to inhaled medication may lead to inadequate symptom control in patients
with respiratory disease. In practice it can be difficult to identify poor adherence. We designed an acoustic
recording device, the INCA® (INhaler Compliance Assessment) device, which, when attached to an inhaler,
identifies and records the time and technique of inhaler use, thereby providing objective longitudinal data
on an individual’s adherence to inhaled medication. This study will test the hypothesis that providing
objective, personalised, visual feedback on adherence to patients in combination with a tailored
educational intervention in a community pharmacy setting, improves adherence more effectively than
education alone.
(Continued on next page)
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Methods/design: The study is a prospective, cluster randomised, parallel-group, multi-site study
conducted over 6 months. The study is designed to compare current best practice in care (i.e. routine
inhaler technique training) with the use of the INCA® device for respiratory patients in a community
pharmacy setting. Pharmacies are the unit of randomisation and on enrolment to the study they will be
allocated by the lead researcher to one of the three study groups (intervention, comparator or control
groups) using a computer-generated list of random numbers. Given the nature of the intervention neither
pharmacists nor participants can be blinded. The intervention group will receive feedback from the
acoustic recording device on inhaler technique and adherence three times over a 6-month period along
with inhaler technique training at each of these times. The comparator group will also receive training in
inhaler use three times over the 6-month study period but no feedback on their habitual performance.
The control group will receive usual care (i.e. the safe supply of medicines and advice on their use). The
primary outcome is the rate of participant adherence to their inhaled medication, defined as the
proportion of correctly taken doses of medication at the correct time relative to the prescribed interval.
Secondary outcomes include exacerbation rates and quality of life measures. Differences in the timing and
technique of inhaler use as altered by the interventions will also be assessed. Data will be analysed on an
intention-to-treat and a per-protocol basis. Sample size has been calculated with reference to comparisons
to be made between the intervention and comparator clusters and indicates 75 participants per cluster.
With an estimated 10 % loss to follow-up we will be able to show a 20 % difference between the
population means of the intervention and comparator groups with a power of 0.8. The Type I error
probability associated with the test of the null hypothesis is 0.05.
Discussion: This clinical trial will establish whether providing personalised feedback to individuals on their
inhaler use improves adherence. It may also be possible to enhance the role of pharmacists in clinical
care by identifying patients in whom alteration of either therapy or inhaler device is appropriate.
Registration: ClinicalTrials.gov NCT02203266.
Keywords: Adherence, INCA® electronic monitor, Cluster randomised trial, Inhaler technique, Community
pharmacy, Patient education
Background
Asthma and chronic obstructive pulmonary disease
(COPD) are common, chronic respiratory diseases [1, 2].
Both conditions are characterised by symptoms such as
wheeze, breathlessness and airflow limitation [3, 4]
which vary in intensity from patient to patient.
Appropriate pharmacological treatment, used correctly,
can help to reduce symptoms and improve quality of life
[3, 4]. Inhaled medications are commonly prescribed but
can be difficult to use and this can lead to technique
errors [5, 6] that may have both direct costs such as medi-
cation waste, and indirect costs such as increased use of
other health care resources as a consequence of poor
symptom control [7].
Community pharmacist-delivered interventions have
been shown to improve inhaler technique [8, 9], inhaled
mediation adherence rates [10] and therapeutic outcomes
[11–14] for adult patients with asthma [8, 9, 11–14] and
COPD [8, 10]. However, adherence rates in reported
studies are frequently either based on patient self-
report which has been shown to be unreliable [15, 16]
or calculated from pharmacy databases containing pre-
scription refill data which provide information on
medication obtained but not on how such medication
is used in practice [17, 18].
We developed a device, INCA®(INhaler Compliance
Assessment), which makes a digital acoustic recording of
an inhaler being used [19]. In this study the device is
attached to a salmeterol/fluticasone Diskus® (Seretide
Diskus®, also known as Seretide Accuhaler®) inhaler.
When a patient opens their Diskus® inhaler (by sliding a
thumbgrip to expose the mouthpiece) the INCA® device
switches on and begins to audio record. The recordings
are analysed using automated signal processing tech-
niques, thus providing an objective assessment of both
time and technique of inhaler use [19].
Participants’ adherence to their inhaled medication will
be described in terms of both attempted and actual
adherence rates. Where the participant opens their
Diskus® inhaler, initiating an audio recording, this is
classed as an attempt to take the inhaled medication.
The pattern of attempts over a defined period will
provide an ‘attempted’ rate of adherence. Analysis of the
associated acoustic recordings allows for detection of
correct inhaler technique, which we take to indicate that
the participant actually received the dose they attempted
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to take. Thus, the pattern of attempted doses with
correct technique yields the ‘actual’ rate of adherence.
We hypothesise that the INCA® device, when used as
part of a community pharmacist-delivered adherence-
focussed educational consultation, can support medica-
tion management in patients with respiratory disease.
Methods
Study setting
This is a prospective, cluster randomised, parallel-group,
multi-site study comparing two pharmacist-delivered
strategies to optimise inhaler technique and adherence
in respiratory patients in the community setting. The
study will be conducted in a chain of 77 community
pharmacies operating in the Republic of Ireland. Phar-
macies are eligible for inclusion in the study if they have
patients who are prescribed a salmeterol/fluticasone
Diskus® inhaler and if those patients have regularly
attended the pharmacy to collect a prescription in the
6 months prior to enrolment. The study period is from
2014 with ongoing recruitment.
Participants
Adult patients of both sexes aged 18 years or older who
use, or are capable of using, a salmeterol/fluticasone
Diskus® inhaler and are in possession of a current valid
prescription for the same, are eligible to enrol on the study.
Inclusion and exclusion criteria
In order to meet inclusion criteria for the study patients
must be capable of understanding, and willing to provide,
voluntary informed consent before any protocol-specific
procedures are performed; be capable of understanding
and complying with the requirements of the study proto-
col; demonstrate a willingness to attend for all required
visits; be able and willing to use inhaled medication and
have a history of regular attendance at the pharmacy in
which they are recruited, receiving at least three prescrip-
tions for any medication filled in the prior 6 months .
Patients are excluded from the study if they have a
known sensitivity to salmeterol/fluticasone, if their phys-
ician has indicated that they will not be continuing to
receive salmeterol/fluticasone Diskus® over the 6-month
study period or if they have used any investigational prod-
uct or device within the 3 months prior to enrolment.
Study design
A cluster randomised study has been chosen in order to
minimise the risk of contamination of knowledge by the
pharmacists across the three study groups. The study
flow is indicated in Fig. 1 (see Additional file 1).
Patients identified in the community pharmacy, who
meet the inclusion and do not violate the exclusion
criteria, will be invited to participate in the study and
are provided with information about the trial in the form
Fig. 1 INCA® Pharmacy Study – overview of study flow and design
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of a participant information leaflet. On enrolment,
consent will be obtained and recorded. All study visits
are conducted by a registered pharmacist.
At the initial visit each participant’s age, sex, dose of
salmeterol/fluticasone, duration of taking this dose and
details of concomitant medications will be recorded on
paper-based case report forms which have been devel-
oped specifically for this study and piloted in a sample
of three pharmacies. The pharmacist will record the
Peak Expiratory Flow Rate (PEFR) as measured by an
electronic peak flow meter (eMini-Wright®, Clement
Clarke International, Harlow, England). The St. George’s
Respiratory Questionnaire (SGRQ) [20], a validated tool
used to assess quality of life in patients with diseases
causing airway obstruction, will be completed by the
participant. A history of inhaled therapy (salmeterol/flu-
ticasone and short-acting beta agonists), steroid and
antibiotic usage over the prior 6 months will be obtained
from the participant’s patient medication record in the
pharmacy. Participants will be asked to identify an
aspect of their life affected by their respiratory condition
that they would like to improve. This ‘breathing-related
goal’ will be recorded and improvement will be moni-
tored through the study period. The purpose of this is to
provide an additional focus for the participant via which
a tangible and personalised measure of any symptom
improvement can be noted. Patient reported clinical
diagnosis (asthma or COPD), smoking status and health
pay status will also be recorded for all participants.
The participants will receive a salmeterol/fluticasone
Diskus® inhaler with an INCA® device attached for use
twice per day as prescribed. This inhaler will be provided
free of charge to all participants, regardless of their
health pay status, with the relevant professional service
being paid by the patient in the usual manner. For all
participants, the INCA® device is used to capture data
on adherence and inhaler technique. Participants in the
intervention and comparator groups will be asked to rec-
ord their peak expiratory flow with the eMini-Wright®
electronic monitor twice daily. In the intervention and
comparator groups participants are also provided with a
paper-based diary for recording daily symptoms, medica-
tion usage and health care utilisation. This diary, based on
the Asthma Society of Ireland’s peak flow diary [21], has
been developed specifically for this study and piloted in a
sample of seven patients. An extract of the diary is
provided in Fig. 2 (see Additional file 1).
After the initial visit (visit 1), follow-up visits are
scheduled 30 (visit 2), 60 (visit 3), 150 (visit 4) and 180
(visit 5) days later. At visits 2, 3 and 5 the participants
return their inhalers with the INCA® devices. Visit 4 is a
dispensing visit. At each of these visits, for control group
participants, changes in medications (including new
medications) are recorded as is progress towards the
participant’s ‘breathing-related goal’. For intervention
and comparator group participants this information is
also noted along with the SGRQ responses. Assessment
of inhaler technique, using an inhaler technique
checklist and inhaler technique training based on as-
sessment observations, is given to both intervention
and comparator participants.
Interventions
Intervention group: feedback using recordings from the
INCA® device
Participants in the intervention group will receive the
INCA® intervention. These participants will receive feed-
back on their own inhaler use, with personalised informa-
tion on their technique and timing of use of the salmeterol/
fluticasone Diskus® inhaler as recorded on the INCA®
Fig. 2 Extract of participant respiratory diary
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device at day 30 (visit 2), day 60 (visit 3) and day 180
(visit 5). Utilising a structured review, the pharmacist
will aim to identify barriers to good adherence and sup-
port patients to improve habit of use where necessary.
Remediation of errors of inhaler use identified through
assessment of participants’ inhaler technique using a
Diskus® inhaler technique checklist, the ‘Inhaler Profi-
ciency Schedule’ (IPS) [22], will also be conducted.
Comparator group: inhaler technique education
The comparator for this study is current best practice
in the community pharmacy setting, defined for this
study as an assessment of the participant’s inhaler
technique using a Diskus® inhaler technique checklist
(IPS) [22] and a physical demonstration of optimal
technique by the pharmacist followed by demons-
tration of the same by the participant until device
mastery is achieved.
Control group: usual care
In order to control for trial participation effects a
control group is included the study design. Participants
in the control group will receive no intervention other
than usual care (i.e. the safe supply of medicines and
advice on their use). Review of inhaler technique, as
initiated by the pharmacist where deemed necessary, or
as requested by the participant, is a feature of usual care
but its provision is not a standard or structured inter-
vention in the control group.
Upon exiting from the study at visit 5, all participants
will receive personalised feedback on their Diskus® use
based on the INCA® device recordings.
Objectives
The objective of this study is to assess whether
providing personalised feedback on adherence and
technique errors will lead to better adherence and
clinical outcomes for participants than current best
practice.
Primary outcome
The primary study objective is to determine whether
there is at least a 20 % greater rate of actual ad-
herence in the INCA® feedback group (‘intervention
group’) compared to the current best practice group
(‘comparator group’) post intervention. Thus, the pri-
mary outcome measure will be the rate of participant
adherence to their inhaled medication, defined as the
proportion of correctly taken drugs at the correct
time relative to the prescribed interval (defined for
this study as the dosing interval ±25 %). To accommo-
date for potential Hawthorne effect comparisons of the
rate of actual adherence at 2 months and at 6 months will
be performed.
Secondary outcome analysis will include
Comparison of the proportion of patients in each group
who achieved good actual adherence (defined for this
study as ≥80 %) as well as the number progressing to
good technique (≥80 % of all doses attempted by the pa-
tient classified as correct technique) at both 2 and
6 months will be assessed. Changes in patterns of adher-
ence in the intervention and comparator groups will also
be reviewed by looking at the morning and evening habit
of inhaler use, error rates, overdose rates, intervals and
attempted rates of adherence.
The PEFRs, SGRQ responses and rescue medication
(inhaler, steroid, antibiotic) use of the intervention and
comparator groups will be compared, as will levels of
reported symptoms (as noted in the participants’ re-
spiratory diaries) and improvement in participants’
‘breathing-related goals’.
Prescription medication dispensing records will be
reviewed to provide a further assessment of adherence
(as defined by the medication possession rates and/or
the proportion of days covered method) pre, during and
post the study, and adherence measured in this way will
be compared across the intervention and comparator
groups; it will also be compared with actual adherence
rates determined by the INCA® device.
Sample size calculation
Studies in the pharmacy setting have identified rates of
baseline rates of attempted adherence amongst asthma
patients of below 0.6 [12]. In the primary care setting poor
inhaler technique amongst patients with respiratory disease
has been identified in preliminary studies conducted using
the INCA® device (47 %, standard deviation 33.0). A pre-
intervention actual adherence rate of 0.5 at the end of the
first month is, therefore, assumed. The primary endpoint is
the rate of actual adherence at the end of the study period.
A comparison between adherence rates in the intervention
and comparator groups will be conducted at the end of
months 1, 2 and 6. The sample size is thus dictated by
comparisons to be made between these two groups.
It is hypothesised that the intervention group will get
closer to the commonly reported level of ‘good’ adherence
(≥0.8) [23] improving by 0.2. Adherence in the compara-
tor group may improve as a result of the educational inter-
vention received and an assumed improvement of 0.05 in
this group over the study period has been incorporated
into the sample size calculation. An intra-class correlation
coefficient of 0.025 and a loss to follow-up of 10 % (as
observed in a recent similar study conducted in the
pharmacy setting [14]) are assumed. With a power of 0.85
at the 0.05 significance level to detect a 0.2 difference in
actual adherence between the two groups, a sample size of
75 participants across 25 clusters in each of the interven-
tion and comparator groups is required.
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Recruitment
Patients attending the study pharmacy who are prescribed
a salmeterol/fluticasone Diskus® inhaler will be identified
via prescription medication records. On attendance to
collect their medication in the pharmacy patients will be
invited to participate in the study. Interested patients will
be screened for eligibility by the pharmacist and if eligible
will be provided with information about the study and a
copy of the patient information leaflet. Voluntary informed
consent will be obtained for all recruited participants.
Randomisation and allocation
Pharmacies are the unit of randomisation and on enrol-
ment to the study they will be allocated by the lead
researcher to one of the three study groups (interven-
tion, comparator or control groups) using a computer-
generated (Microsoft Excel® 2013) list of random numbers.
In order to control for trial participation effects 10
pharmacies will be randomly allocated to the control
group. Remaining pharmacies will then be randomly
allocated to either the intervention or comparator
group in a 1:1 ratio. Given the nature of the intervention
neither pharmacists nor participants can be blinded. All
participants are aware that data on adherence are being
collected for analysis and a lead-in period is incorpo-
rated into the study design to account for a potential
Hawthorne effect.
Pharmacist training
Pharmacists will deliver the intervention allocated to the
pharmacy in which they practise and they will receive
training specific to that intervention. Training will consist
of one 1.5-hour face-to-face workshop with a respiratory
physician, nurse specialist and pharmacist educator/re-
searcher where they will be provided with an overview of
the study and trained to provide education on inhaler
technique and medication adherence. A distance learning
study guide specific to each study arm and outlining all
study-related procedures will also be completed. Through-
out the study pharmacists will be supported by a lead
pharmacy researcher who will be available via phone or
email to answer any queries they may have.
Data collection, management and analysis
Data collection
Pharmacists completing data collection are trained to
understand the importance of robust data collection, are
provided with a study guidance pack outlining all rele-
vant data collection procedures and sign a declaration
indicating their agreement to keep complete and accur-
ate records. The accuracy, completeness and progress of
data will be overseen by a lead researcher in the
pharmacy chain where the study is being conducted.
This researcher, who will have no role in participant
recruitment or in conducting any study-related proce-
dures, will conduct visits to the study pharmacies to
check compliance with the protocol.
Every reasonable effort to follow up all enrolled par-
ticipants for the entire 6-month study period will be
employed. At each study visit an appointment for the
next visit will be scheduled and non-attenders will be
contacted to re-schedule as required. The lead pharma-
cist researcher will monitor recruitment and retention
and target counselling and training interventions to
pharmacy sites where retention is a challenge. At any
point in time, a study participant is free to withdraw
their consent from the study. A patient can be with-
drawn from the study by the investigator if necessary,
based on clinical assessment of adverse events, or in the
event of early discontinuation of the study. In the case
of withdrawing from the study, consultation will be
completed where possible and their adapted inhaler,
peak flow meter and diary will be collected.
Safety reporting
Safety testing and a comprehensive risk assessment have
been conducted in an effort to minimise potential hazards
associated with the clinical investigation of this device.
The INCA® device will be securely fixed to the outer
casing of the inhaler. It does not interfere in any way with
the inhaler’s mechanism of drug delivery. However, in the
event of any safety issues arising adverse events and
serious adverse events will be recorded in the case report
form and evaluated by the lead pharmacy investigator.
The principle investigator, ethics committees and the
Health Products Regulatory Authority (HPRA) will be no-
tified of any serious adverse events that occur. In addition,
information about device-related adverse events will be
collected and reported to the manufacturer of the device
and the HPRA. Drug-related serious adverse events will
be reported to the manufacturer of the drug.
Data management
Paper-based case report forms will be pseudonymised
with a unique patient identifier code. On study com-
pletion or withdrawal, data from these report forms
will be input by the lead researcher into an electronic,
password-protected database. Participant files will
remain locked in a secure and accessible place, in a
manner consistent with local data protection requi-
rements, and maintained in storage for a period of
3 years post termination of the study.
Audio data will be uploaded to a secure server, access
to which is by individual user name and password.
Individual pharmacists will not have access to this data-
base. The tool has an inbuilt audit trail that records, and
can display, details of additions or changes made to data
either on a by-user or a by-patient basis.
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Analysis of the audio data
The INCA® device is a Conformité Européene (CE)-
marked device which is manufactured by Vitalograph,
Ennis, Ireland. Digital recordings from the INCA® device
are analysed as previously described [19]. The files are
uploaded to a secure server and analysed using signal pro-
cessing methods. The sensitivity and specificity details of
the signal processing algorithm have been published [24].
The algorithm identifies each audio file as one represent-
ing either correct or incorrect inhaler use as well as auto-
matically classifying any technique errors identified. Two
independent human raters also over-read all files from all
participants in order to validate the data. Comparison is
made between the automated and human classification as
well as between the classifications of the two independent
raters. In the event of any disagreement, review by a third
over-reader yields the final classification by majority deci-
sion. The final classification is then used in the calculation
of the actual adherence. The human raters are independ-
ent of any patient care during the trial and are blinded to
the randomisation status of the patient. Critical inhaler
errors which can occur include failure to prime the
inhaler with drug, exhalation into or near the mouthpiece
after priming but before inhalation, failure to achieve an
adequate flow rate and the presence of multiple inhala-
tions indicating inadequate breath-holds. Non-critical er-
rors such as not holding the device level are not recorded.
Statistical methods
Statistical analysis will be conducted using IBM SPSS
Statistics for Windows, Version 21.0. (Armonk, NY,
USA: IBM Corp). Descriptive statistics will be used to
evaluate differences in demographic characteristics,
clinical condition, medication profile, exacerbation his-
tory and quality of life scores between study groups. Cat-
egorical variables will be expressed as frequencies or
percentages and quantitative variables as means and
standard deviations or medians and interquartile ranges.
The primary analysis will be carried out using multi-
level modelling (such as mixed linear effects modelling)
with the individual as the unit of analysis and controlling
for the effects of clustering and baseline differences. An
intention-to-treat analysis will be conducted. A second-
ary, per-protocol analysis will also be conducted. This
form of analysis includes only those participants who
completed the treatment protocol originally allocated,
providing results on the efficacy of the trial.
The proportion of patients achieving good actual adher-
ence (≥80 %) and the proportion progressing to good
technique (≥80 % of all doses attempted by the patient
classified as correct technique) will be analysed using a
random-effects logistic regression with the individual as
the unit of analysis and the pharmacy included as the
random effect, to control for the effects of clustering.
Changes in patterns of adherence will also be investi-
gated. PEFR, rescue medication use and reported symp-
toms will be described and used as an indicator of the
number of exacerbations per patient which will, in turn,
be compared between the groups. Additionally, differ-
ences in the SGRQ responses will be examined. For all
analyses stratification of patients by diagnosis will be
attempted but consideration will be given to the ability
to make inferences based on patient numbers.
A full statistical analysis plan will be written by an inde-
pendent statistical team prior to any analysis being under-
taken. Data will be reported in line with the Consolidated
Standards of Reporting Trials (CONSORT) 2010 State-
ment [25] as well as its extension to cluster randomised
trials [26] and non-pharmacological treatment [27].
Discussion
The aim of this study is to evaluate the extent to
which a community pharmacist-delivered intervention
combining monitored adherence with repeated perso-
nalised education can improve inhaler technique and
adherence in patients with respiratory disease. This is
the first community pharmacy-based study to use a
technology that objectively assesses appropriate use of
inhalers both in terms of technique of use as well as
time of use, permitting longitudinal evaluation of patients’
habitual performance when not under direct visual
observation. This technology incorporates a novel
electronic device, automated algorithms and feedback
tools including graphical representations of adher-
ence, facilitating personalised feedback provided by
the pharmacist.
Pharmacists are increasingly involved in comprehen-
sive medication management [28]. In order to optimise
clinical outcomes for their shared patients close col-
laboration between pharmacists and physicians is likely
to be required [29]. Provision of high-quality clinical
recommendations that improve patient outcomes is
important in establishing trust [30], a key component of
successful pharmacist/physician collaboration [29, 31].
Collecting objective longitudinal information on inhaler
adherence may support the formulation by the phar-
macist of such recommendations, thus supporting the
collaborative clinical decision-making process. It is ex-
pected that some participants may become fully adher-
ent, with others continuing to demonstrate variable or
poor adherence over the study period. Combining this
information with clinical measures such as PEFR data
and exacerbation rates may support inter-professional
decision-making for individual patients by potentially
distinguishing between patients who would benefit from
further interventions to promote adherence as opposed
to those in whom therapy adjustment or change of
inhaler device may be more appropriate.
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As INCA records comprise a much richer dataset than
other adherence measures that are routinely available for
patients in primary care (primarily prescription refill and
dose counter information), analysis of the nature, preva-
lence and persistence of timing and technique errors
identified by the INCA® device should also lead to a
deeper understanding of adherence and the barriers to
effective Diskus® use, potentially facilitating development
of proactive countermeasures for all patients. Analysis of
the study data will also provide a means of assessing the
reliability of conventional adherence measures in identi-
fying and assessing adherence.
The study has a number of limitations. Patients with
asthma and/or COPD are eligible to join the study mean-
ing that there is a lack of sample homogeneity with
respect to clinical condition. Stratification by condi-
tion at point of analysis will be attempted, but such
analysis may lack sufficient power to make valuable
inferences meaning that the study may be limited in
its generalisability.
Patients requiring regular medication for the treatment
of a chronic condition, such as asthma or COPD, are not
required to register with an individual pharmacy in the
Republic of Ireland meaning that they are free to move
between pharmacies when collecting their monthly medi-
cation. To avoid the situation where patients collecting a
prescription for a salmeterol/fluticasone Diskus® inhaler in
a study pharmacy as a one-off occurrence are recruited to
the study (leading to greater potential for attrition) the
inclusion criteria specify that the patient must have had at
least three prescriptions for any medication filled in the
study pharmacy in the prior 6 months. Whilst the three
prescriptions do not need to have been for a salmeterol/
fluticasone Diskus® inhaler this nevertheless raises the
possibility that patients with adherence rates of at least 0.5
at baseline will be recruited. However, given that ad-
herence rates based on prescription records frequently
overestimate adherence [32], and as the INCA device is
designed to assess actual adherence (defined as the num-
ber of doses taken correctly at the correct time), we feel
that this is justified.
As with other cluster randomised trials where allo-
cation concealment is not possible there is a risk of
selection bias [33, 34] both from the pharmacist and
participant perspective. To minimise such bias pharma-
cists in each individual site are trained to recognise the
importance of unbiased recruitment and recruitment to
each site is monitored by the lead pharmacist researcher
so that potential bias can be identified and addressed
through further counselling and/or training as required.
There is a potential for loss to follow-up. To minimise
these losses, participants not attending for study visits at
scheduled times will be contacted by telephone a max-
imum of three times. Potential loss to follow-up has been
accounted for in the sample size estimation and will
be taken account of in the intention-to-treat analysis
of study data.
Trial status
Ongoing, currently recruiting participants.
Ethical approval and consent to participate
The use of the INCA device in clinical investigation trial
has been approved by the Irish Medicines Board (now
Health Products Regulatory Authority) and the device is
CE marked (CE0086). The study has been approved by
Royal College of Surgeons in Ireland Ethics Committee
(REC712b) and is registered as NCT02203266 on Clinical-
Trials.gov (27 July 2014). The study will be conducted
according to the principles of the Declaration of Helsinki
(64th WMA General Assembly, Fortaleza, Brazil, October
2013), international standards of Good Clinical Practice,
local regulatory requirements and this study protocol. In
the event of any changes to the protocol a written appli-
cation will be submitted to the Research Ethics Commit-
tee prior to implementation. Informed consent will be
obtained from all participants.
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